SCHEMBL4033245

SCHEMBL4033245

OCCn1nc(-c2ccc(O)c(O)c2)c2cc(Cl)c(F)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.44
RORC P51449 1/20 0.37
MDM4 O15151 3/20 0.35
MDM2 Q00987 3/20 0.35
TGFBR1 P36897 3/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
TGFBR2 P37173 1/20 0.32
ALOX5 P09917 1/20 0.32
MARS1 P56192 1/20 0.32
ESR2 Q92731 1/20 0.32
PIK3CD O00329 1/20 0.31
ABL1 P00519 1/20 0.31
EGFR P00533 1/20 0.31
HCK P08631 1/20 0.31
SRC P12931 1/20 0.31
KDR P35968 1/20 0.31
PIK3CA P42336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032378 0.95 ESR1 (0.44) ESR1RORCMDM4MDM2TGFBR1
SCHEMBL4028980 0.88 ESR1 (0.57) ESR1RORCMDM4MDM2MARS1
SCHEMBL4025974 0.87 ESR1 (0.47) ESR1RORCPIK3CDABL1EGFR
SCHEMBL4028787 0.84 ESR1 (0.47) ESR1RORCPDE4APDE4BPDE4C
SCHEMBL4029086 0.83 ESR1 (0.57) ESR1RORCMDM4MDM2MARS1
SCHEMBL4029614 0.83 ESR1 (0.39) ESR1ALOX5ESR2PIK3CDABL1
SCHEMBL4034670 0.81 ESR1 (0.43) ESR1RORCALOX5MARS1
SCHEMBL4034694 0.79 ESR1 (0.47) ESR1RORCPDE4APDE4BPDE4C
SCHEMBL4197102 0.76 ESR1 (0.44) ESR1RORC
SCHEMBL4025242 0.76 ESR1 (0.44) ESR1RORCSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR ESR1 1028/4885RORC 142/4885MDM4 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.